帮助 关于我们

返回检索结果

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

查看参考文献21篇

文摘 Background: There was still conflict on the antithrombotic advantage of ticagrelor versus clopidogrel among East Asian population with acute coronary syndrome (ACS). We considered that the baseline bleeding risk might be an undetected key factor that significantly affected the efficacy of ticagrelor. Methods: A total of 20,816 serial patients who underwent percutaneous coronary intervention (PCI) from October 2011 to August 2014 in the General Hospital of Shenyang Military Region were enrolled in the present study. Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk. The primary outcome was net adverse clinical events (NACEs) defined as major adverse cardiac or cerebral events (MACCE, including all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, or stroke) and any bleeding during 1-year follow-up. Comparison between ticagrelor and clopidogrel was adjusted by propensity score matching (PSM). Results: Among the 20,816 eligible PCI patients who were included in this study, there were 1578 and 779 patients in the clopidogrel and ticagrelor groups, respectively, after PSM, their clinical parameters were well matched. Patients receiving ticagrelor showed comparable NACE risk compared with those treated by clopidogrel (5.3% vs. 5.1%,P = 0.842). Furthermore, ticagrelor might reduce the MACCE risk in patients with low bleeding risk but increase MACCE in patients with moderate-to-high bleeding potential (ticagrelor vs. clopidogrel, low bleeding risk: 2.5% vs. 4.9%, P = 0.022; moderate-to-high bleeding risk: 4.8% vs. 3.0%, P = 0.225; interaction P = 0.021), with vast differences in all bleeding (low bleeding risk: 1.5% vs. 0.8%, P = 0.210; moderate-to-high bleeding risk: 4.8% vs. 3.0%, P = 0.002; interaction P = 0.296). Conclusion: Among real-world Chinese patients with ACS treated by PCI, ticagrelor only showed superior efficacy in patients with low bleeding risk but lost its advantage in patients with moderate-to-high bleeding potential.
来源 Chinese Medical Journal ,2018,131(17):2017-2024 【核心库】
DOI 10.4103/0366-6999.239306
关键词 Baseline Bleeding Risk ; Clopidogrel ; Crusade Score ; Efficacy ; Ticagrelor
地址

Department of Cardiology, General Hospital of Shenyang Military Region, Liaoning, Shenyang, 110016

语种 英文
文献类型 研究性论文
ISSN 0366-6999
学科 医药、卫生
基金 sponsored by a grant from the National Key Research and Development Project
文献收藏号 CSCD:6311999

参考文献 共 21 共2页

1.  Authors/Task Force Members. 2014 ESC/EACTS guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society Of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS) Developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J,2014,35:2541-2619 被引 151    
2.  Levine G N. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol,2016,67:1235-1250 被引 42    
3.  Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med,2009,361:1045-1057 被引 201    
4.  Steg P G. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation,2010,122:2131-2141 被引 19    
5.  Sahlen A. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: Experiences from SWEDEHEART registry. Eur Heart J,2016,37:3335-3342 被引 5    
6.  Goto S. Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome - Randomized, double-blind, phase III PHILO study. Circ J,2015,79:2452-2460 被引 10    
7.  Wu B. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: A meta-analysis of randomized trials. J Comp Eff Res,2018,7:281-291 被引 3    
8.  Lee C H. Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. Clopidogrel in Taiwan. Circ J,2018,82:747-756 被引 5    
9.  Chen I C. Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. J Chin Med Assoc,2016,79:521-530 被引 4    
10.  Hamon M. Prognostic impact of major bleeding in patients with acute coronary syndromes. A systematic review and meta-analysis. Eurolntervention,2007,3:400-408 被引 2    
11.  Cornara S. Prognostic impact of in-hospital-bleeding in patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol,2017,120:1734-1741 被引 3    
12.  Levine G N. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol,2014,11:597-606 被引 22    
13.  Kang H J. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J,2015,169:899-905.el 被引 14    
14.  Wang X. Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: Insight into contemporary practice in Chinese patients. Eur Heart J Suppl,2016,18:F19-F26 被引 3    
15.  Subherwal S. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can rapid risk stratification of unstable angina patients suppress ADverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score. Circulation,2009,119:1873-1882 被引 46    
16.  Mehran R. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation,2011,123:2736-2747 被引 135    
17.  Wang H. Pharmacodynamics and pharmacokinetics of ticagrelor vs. Clopidogrel in patients with acute coronary syndromes and chronic kidney disease. Br J Clin Pharmacol,2018,84:88-96 被引 5    
18.  Teng R. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and caucasian volunteers. Int J Clin Pharmacol Ther,2014,52:478-491 被引 8    
19.  Kwon T J. Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. Thromb Haemost,2016,115:979-992 被引 1    
20.  Yeh R W. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA,2016,315:1735-1749 被引 14    
引证文献 3

1 李毅 中国冠心病抗栓治疗的进展与展望 中华心血管病杂志,2019,47(9):683-688
被引 0 次

2 中华医学会心血管病学分会 急性ST段抬高型心肌梗死诊断和治疗指南(2019) 中华心血管病杂志,2019,47(10):766-783
被引 124

显示所有3篇文献

论文科学数据集
PlumX Metrics
相关文献

 作者相关
 关键词相关
 参考文献相关

版权所有 ©2008 中国科学院文献情报中心 制作维护:中国科学院文献情报中心
地址:北京中关村北四环西路33号 邮政编码:100190 联系电话:(010)82627496 E-mail:cscd@mail.las.ac.cn 京ICP备05002861号-4 | 京公网安备11010802043238号